CorMedix Outlines Post-Melinta Growth, Q2 REZZAYO Phase 3 Catalyst and DefenCath Reimbursement Shift [Yahoo! Finance]
CorMedix Inc. (CRMD)
NASDAQ:AMEX Investor Relations:
cormedix.com
Company Research
Source: Yahoo! Finance
adds REZZAYO , with a global Phase 3 prophylaxis readout expected in Q2 that could expand the label beyond treatment (current treatment TAM ~$250–$350M) if fungal-free survival and pathogen-specific data are strong. DefenCath reimbursement shift and volume strategy: TDAPA reimbursement for DefenCath moves to a bundled adjustment on July 1, creating a likely short-term “subpar” add-on in Q3–Q4 2026 that the company plans to mitigate via temporary price concessions and customer negotiations, while targeting volume growth from one large remaining customer and greater Medicare Advantage contracting. Financial position and capital plans: CorMedix ended the year with about $150M in cash and $150M in debt (net zero), has launched a up-to-$75M share buyback program, and is prioritizing tuck-in business development while leaning on REZZAYO and existing anti-infectives for growth. Interested in CorMedix Inc? Here are five stocks we like better. High Risk, High Reward: 3 Healthcare Stock
Show less
Read more
Impact Snapshot
Event Time:
CRMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRMD alerts
High impacting CorMedix Inc. news events
Weekly update
A roundup of the hottest topics
CRMD
News
- CorMedix: A Shrinking Core And No Proven Second Engine [Seeking Alpha]Seeking Alpha
- CorMedix to Participate in Needham Virtual Healthcare ConferenceGlobeNewswire
- CorMedix: Waiting On Phase III ReSPECT For A Further Re-Rating (Upgrade) [Seeking Alpha]Seeking Alpha
- How The CorMedix (CRMD) Investment Story Is Shifting As Analyst Targets Reset [Yahoo! Finance]Yahoo! Finance
- CorMedix CEO touts Melinta pivot, DefenCath TDAPA transition and Q2 REZZAYO Phase 3 data at Leerink [Yahoo! Finance]Yahoo! Finance
CRMD
Earnings
- 3/5/26 - Miss
CRMD
Sec Filings
- 4/17/26 - Form PRE
- 3/26/26 - Form SCHEDULE
- 3/6/26 - Form 8-K
- CRMD's page on the SEC website